Scimitar and DVLP Medicines Announce Strategic Partnership to Revolutionize Drug Development Speed and Efficiency
DVLP Medicines and Scimitar enter a strategic collaboration, pairing the ability to accelerate end-to-end development operations through DVLP's AI platform with Scimitar's operational expertise in implementation and change management.
Scimitar, a leading management consulting firm specializing in life sciences, and DVLP Medicines, the pioneer of the industry's first end-to-end integrated development platform, today announced a strategic collaboration designed to fundamentally accelerate how life-changing therapies reach the market.
By combining DVLP's groundbreaking technology with Scimitar's deep expertise in organizational transformation and implementation, the partnership aims to deliver productivity gains exceeding 30% for pharmaceutical and biotech companies.
A New Standard for Pharmaceutical Development
The drug development process has historically been hindered by fragmented data and legacy silos. DVLP Medicines solves this by centralizing all development content onto a single, cohesive platform. This integration enables a suite of "one-click" capabilities that were previously thought impossible:
- Development Plan: Instantaneous generation of comprehensive strategic roadmaps.
- Data Room: Seamless, secure preparation for due diligence and licensing.
- One-Click IND/BLA Submission: Automating the transition from data to regulatory filing.
- Portfolio Optimizer: Real-time data visualization to prioritize the most promising assets.
While DVLP provides the "engine" for this capability, Scimitar provides the "customization and infrastructure." leading the change management, software customization, and implementation necessary to ensure that biopharma companies can fully absorb and capitalize on these technological leaps.
"We see AI-readiness as essential for truly cutting-edge biopharmaceutical companies to compete but have seen most of our clients struggle with finding the right 'pin-point' solutions that are proven to move the needle", said Zeid Barakat, Partner at Scimitar. "With DVLP, it is like an end-to-end "operating system upgrade", and we've seen incredible results, with clients developing INDs and development plans in days vs. months. It is incredibly exciting to see what our clients can do with this new level of productivity, and to see life-saving medicines reach patients that much faster".
About DVLP Medicines
DVLP Medicines is a technology-first life sciences company. Its proprietary platform serves as a single source of truth for all drug development content, enabling automated submissions, strategic planning, and portfolio management through a streamlined, user-centric interface.
Interested in learning more? Please contact info@scimitar.com
